Looking for Growth? Forget Cannabis. Go Retro With These 2 Previous Growth Kings

Do Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) and BlackBerry Ltd. (TSX:BB)(NYSE:BB) really have more upside than cannabis firms or companies such as Shopify Inc. (TSX:SHOP)(NYSE:SHOP)?

The Motley Fool
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Canada has had many darling growth companies over the years, and with the rise of the cannabis industry and technology companies such as Shopify Inc. (TSX:SHOP)(NYSE:SHOP), perhaps a new dawn is on the horizon, and Canadians need to focus on the new kids on the block.

That being said, I’m going to touch on two previous Canadian growth gems and discuss why they may not be all that “washed up” compared to the up-and-coming competition.

Valeant

One of my previous picks for a turnaround play in 2017 was Canadian pharmaceutical giant Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX). The thesis behind Valeant has not changed, and since the beginning of 2017, Valeant has actually performed quite well, up more than 45% over the past 52 weeks alone.

The company’s management team has done an excellent job of paying down debt, already far exceeding a short-term goal of $5 billion in debt reductions, and it has begun to focus on generating growth through its core drug segments, which are poised to take advantage of high-growth potential in the years to come.

With a large debt overhang still encumbering Valeant, the question will be whether the expected growth from the products in Valeant’s pipeline will live up to expectations and provide enough organic cash flow to begin paying down debt the old-fashioned way, avoiding further debt restructurings or asset sales.

BlackBerry

In the tech sector, BlackBerry Ltd. (TSX:BB)(NYSE:BB) has really begun to turn the corner as of approximately mid-2017. Over the past 52 weeks, BlackBerry has provided investors with a return of no less than 77.5% — not too shabby for a company that many wrote off a long time ago, and one which has largely been forgotten by many investors who’ve taken big losses over the past decade.

The company has done an excellent job of transitioning toward a pure-play software company, away from its traditional hardware roots. With ambitions of becoming a top global player in software supporting the autonomous vehicle segment, BlackBerry has a significant amount of upside should the company’s management team continue to exceed expectations in the quarters and years to come.

Bottom line

The Canadian cannabis sector and technology companies like Shopify have proven their ability to dole out quick double-digit (or even triple-digit) returns to investors willing to make the momentum bet that all will continue in perpetuity and everything will go according to plan.

BlackBerry and Valeant are two companies which show what can happen when complacency sets in for growth companies on the “expectations treadmill.” Every earnings report, investors will demand outsized growth returns; anything less, and a sharp correction could be in order.

With BlackBerry and Valeant now off the treadmill and on the path to creating organic growth, these companies offer better long-term fundamentals, in my opinion, then the aforementioned young up-and-coming TSX growth players.

Stay Foolish, my friends.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any stocks mentioned in this article. Tom Gardner owns shares of Shopify and Valeant Pharmaceuticals. The Motley Fool owns shares of Blackberry, Shopify, SHOPIFY INC, and Valeant Pharmaceuticals. Shopify is a recommendation of Stock Advisor Canada.

More on Tech Stocks

A worker uses a double monitor computer screen in an office.
Tech Stocks

Why Shopify Stock Sold Off Last Week

Shopify (TSX:SHOP) sold off heavily last week. A bad earnings release may have been the culprit.

Read more »

Hand arranging wood block stacking as step stair with arrow up.
Tech Stocks

2 Phenomenal Growth Stocks Down 30-60% That Could Rally in the Next Bull Market

Is it time to buy growth stocks? The worst of the interest rate hike and inflation is over, and now…

Read more »

stock market
Tech Stocks

2 Best Tech Stocks to Buy Before the Next Bull Market

Tech stocks such as Roku and Nuvei can help long-term investors generate outsized gains in 2023 and beyond.

Read more »

Wireless technology
Tech Stocks

Tucows Stock Trades Near its 6-Year Low: Is it a Buy?  

Tucows stock fell 63% in the tech stock sell-off and has failed to show any recovery. Is this domain and…

Read more »

Male IT Specialist Holds Laptop and Discusses Work with Female Server Technician. They're Standing in Data Center, Rack Server Cabinet with Cloud Server Icon and Visualization
Tech Stocks

Is Converge Stock a Buy?

A relatively new tech stock could soar higher with the pause in rate hikes, although a resumption of the cycle…

Read more »

online shopping
Tech Stocks

Up by 25%: Is Shopify Stock Finally a Buy in 2023?

The strong rebound in the TSX’s top tech stock remains uncertain. Investors will have to wait before it delivers stellar…

Read more »

Businessman holding AI cloud
Tech Stocks

2 TSX Tech Stocks Innovating Hard in AI

Shopify (TSX:SHOP) stock and another intriguing Canadian gem make good use of AI technologies.

Read more »

worry concern
Tech Stocks

Shopify Stock: Incredible Bargain or Deceptive Trap?

Shopify has quickly shifted from a market darling to something else. Is it a safe buy or risqué bet?

Read more »